renal cell carcinoma

Summary

Summary: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.

Top Publications

  1. ncbi Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    Cora N Sternberg
    FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, Italy 00152
    J Clin Oncol 28:1061-8. 2010
  2. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
  3. ncbi HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability
    Jennifer S Isaacs
    Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Cell 8:143-53. 2005
  4. ncbi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
  5. ncbi Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
  6. ncbi Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
    Dorothy A White
    Memorial Sloan Kettering Cancer Center, Pulmonary Medicine, New York, NY 10021, USA
    Am J Respir Crit Care Med 182:396-403. 2010
  7. ncbi Tumor-to-tumor metastasis: Renal cell carcinoma metastatic to papillary carcinoma of thyroid-report of a case and review of the literature
    Olga L Bohn
    Department of Pathology, MetroHealth Medical Center Case Western Reserve University, Cleveland, OH 44109, USA
    Head Neck Pathol 3:327-30. 2009
  8. ncbi Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 27:4462-8. 2009
  9. ncbi Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma
    Huiqing Liu
    BioMaPS Institute, Rutgers University, Piscataway, NJ 08854, USA
    BMC Syst Biol 4:51. 2010
  10. ncbi Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
    Sergei Kusmartsev
    Department of Urology, College of Medicine, University of Florida, Gainesville, Florida 32610 0247, USA
    Clin Cancer Res 14:8270-8. 2008

Research Grants

  1. Targeting Tumor Angiogenesis with SAHA and Bevacizumab in Kidney Cancer
    Roberto Pili; Fiscal Year: 2007
  2. Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma
    EUGENE D contact KWON; Fiscal Year: 2010
  3. Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma
    Eugene Kwon; Fiscal Year: 2009
  4. Regulation of nitrogen catabolic gene expression in S cerevisiae
    Terrance G Cooper; Fiscal Year: 2010
  5. Regulation of nitrogen catabolic gene expression in S cerevisiae
    TERRANCE COOPER; Fiscal Year: 2007
  6. PAX2 INTERACTING PROTEINS IN DEVELOPMENT AND DISEASE
    Gregory Dressler; Fiscal Year: 2009
  7. Systemic AA Amyloidosis Inhibitors
    ALAN SNOW; Fiscal Year: 2004
  8. Mechanism of Gene Repression in the Kidney
    SANJEEVKUMAR PATEL; Fiscal Year: 2009
  9. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    Joseph Bonventre; Fiscal Year: 2007
  10. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    JOSEPH VINCENT BONVENTRE; Fiscal Year: 2010

Detail Information

Publications290 found, 100 shown here

  1. ncbi Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    Cora N Sternberg
    FACP, Department of Medical Oncology, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, Rome, Italy 00152
    J Clin Oncol 28:1061-8. 2010
    ..and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)...
  2. ncbi Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:3312-8. 2009
    ..data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported.
  3. ncbi HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability
    Jennifer S Isaacs
    Urologic Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Cell 8:143-53. 2005
    ..Further, we show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for regulating HPH activity and HIF protein levels...
  4. ncbi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with ..
  5. ncbi Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 116:4256-65. 2010
    ..trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor-tyrosine kinase inhibitors...
  6. ncbi Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
    Dorothy A White
    Memorial Sloan Kettering Cancer Center, Pulmonary Medicine, New York, NY 10021, USA
    Am J Respir Crit Care Med 182:396-403. 2010
    ..Objectives: To assess the incidence, radiographic patterns, management, and outcome of pneumonitis in patients with advanced renal cell carcinoma receiving everolimus.
  7. ncbi Tumor-to-tumor metastasis: Renal cell carcinoma metastatic to papillary carcinoma of thyroid-report of a case and review of the literature
    Olga L Bohn
    Department of Pathology, MetroHealth Medical Center Case Western Reserve University, Cleveland, OH 44109, USA
    Head Neck Pathol 3:327-30. 2009
    Metastatic disease to thyroid gland is a rare event. Although renal cell carcinoma (RCC) has been reported to metastasize the thyroid gland, metastatic RCC to a thyroid neoplasm is very unusual...
  8. ncbi Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 27:4462-8. 2009
    ..potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3 in patients with metastatic renal cell carcinoma (mRCC) refractory to prior therapies that included, but were not limited to, sorafenib.
  9. ncbi Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma
    Huiqing Liu
    BioMaPS Institute, Rutgers University, Piscataway, NJ 08854, USA
    BMC Syst Biol 4:51. 2010
    ..Putative mRNA targets of microRNA identified from seed sequence matches are available in many databases. However, such matches have a high false positive rate and cannot identify tissue specificity of regulation...
  10. ncbi Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
    Sergei Kusmartsev
    Department of Urology, College of Medicine, University of Florida, Gainesville, Florida 32610 0247, USA
    Clin Cancer Res 14:8270-8. 2008
    ..immunosuppression remains a significant obstacle that limits the efficacy of biological therapy for renal cell carcinoma. Here we evaluate the role of CD33 myeloid-derived suppressor cells (MDSC) in the regulation of T-cell ..
  11. ncbi Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 28:2137-43. 2010
    Bevacizumab is an antibody that binds vascular endothelial growth factor and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN-alpha) is the historic standard initial treatment for RCC...
  12. ncbi Liver resection for metastases from renal cell carcinoma
    Armin Thelen
    Departmant of General, Visceral and Transplantation Surgery, Campus Virchow Klinikum, Charite Universitaetsmedizin Berlin, Berlin, Germany
    World J Surg 31:802-7. 2007
    This study was conducted to evaluate the safety and efficacy of liver resection in patients with hepatic metastases from renal cell carcinoma and to identify selection criteria for patients suitable for resection.
  13. ncbi Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
    James H Finke
    Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Clin Cancer Res 14:6674-82. 2008
    Immune dysfunction is well documented in renal cell carcinoma (RCC) patients and likely contributes to tumor evasion...
  14. ncbi Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    Gary Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    N Engl J Med 356:2271-81. 2007
    ..Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease...
  15. ncbi Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma
    Lei Li
    Institute of Urology, The 1st Affiliated Hospital, Xi an Jiaotong University, 277, YanTa Western Road, Xi an, Shaanxi 710061, China
    Cancer Lett 272:61-9. 2008
    ..However, whether it could inhibit renal cell carcinoma growth and what are the underlying mechanisms is still not well elucidated...
  16. ncbi Clinical significance of Galectin-3 in clear cell renal cell carcinoma
    Manabu Sakaki
    Department of Urology, Institute of Health Biosciences, University of Tokushima Graduated School, Tokushima, Japan
    J Med Invest 57:152-7. 2010
    ..In this study, we investigated the expression of galectin-3 in clear cell renal cell carcinoma (CC-RCC) and evaluated the relationship between galectin-3 expression levels and the clinicopathological ..
  17. ncbi Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia
    Peter Schraml
    Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
    Mod Pathol 22:31-6. 2009
    Renal cysts and clear cell renal cell carcinoma are common clinical manifestations of people with germ-line mutations of the von Hippel-Lindau tumor suppressor gene, VHL...
  18. ncbi The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
    Daniel C Cho
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 16:3628-38. 2010
    Inhibitors of TORC1 have been shown to be active in patients with metastatic renal cell carcinoma (RCC)...
  19. ncbi Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
    Ian P M Tomlinson
    Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, 44, Lincoln s Inn Fields, London WC2A 3PX, UK
    Nat Genet 30:406-10. 2002
    ..We previously mapped a gene that predisposes to multiple fibroids, cutaneous leiomyomata and renal cell carcinoma to chromosome 1q42.3-q43 (refs 4-6)...
  20. ncbi Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
    Howard L Kaufman
    Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
    J Transl Med 7:2. 2009
    Interleukin-2 (IL-2) induces durable objective responses in a small cohort of patients with metastatic renal cell carcinoma (RCC) but the antigen(s) responsible for tumor rejection are not known...
  21. ncbi The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma
    Tsz fung F Chow
    Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    J Urol 183:743-51. 2010
    ..We previously identified 80 miRNAs that are dysregulated in clear cell renal cell carcinoma. In this study we validated over expression of the miR-17-92 cluster in clear cell renal cell carcinoma and ..
  22. ncbi Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
    Jennifer S Ko
    Department of Immunology, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA
    Clin Cancer Res 15:2148-57. 2009
    Immune dysfunction reported in renal cell carcinoma (RCC) patients may contribute to tumor progression. Myeloid-derived suppressor cells (MDSC) represent one mechanism by which tumors induce T-cell suppression...
  23. ncbi Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
    Bernard Escudier
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    J Clin Oncol 27:1280-9. 2009
    ....
  24. ncbi Association of microRNA-34a overexpression with proliferation is cell type-dependent
    Khokon Kumar Dutta
    Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University, Kyoto 606 8501, Japan
    Cancer Sci 98:1845-52. 2007
    ....
  25. ncbi Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes
    Paulo C Rodriguez
    Department of Microbiology, Stanley S Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Cancer Res 69:1553-60. 2009
    ..suppressor cells (MDSC) producing arginase I are increased in the peripheral blood of patients with renal cell carcinoma (RCC)...
  26. ncbi HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma
    Belén Lucas
    Institut für Zellbiologie Tumorforschung, Universitatsklinikum Essen, D 45122 Essen, Germany
    Oncogene 24:6418-31. 2005
    ..The abundance and activity of HNF4alpha are frequently reduced in renal cell carcinoma (RCC) indicating some tumor suppressing function of HNF4alpha in renal cells...
  27. ncbi The long-term outcome of laparoscopic radical nephrectomy for small renal cell carcinoma
    Y Ono
    Department of Urology, Nagoya University School of Medicine and Shakaihoken Chukyo Hospital, Nagoya, Japan
    J Urol 165:1867-70. 2001
    PURPOSE: To evaluate the efficacy of laparoscopic radical nephrectomy in patients with small renal cell carcinoma, we analyzed the long-term results in those treated with laparoscopy and those undergoing open surgery...
  28. ncbi Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
    Dan Huang
    Laboratory of Cancer Genetics, Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 70:1063-71. 2010
    The broad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer...
  29. ncbi HIF-1 mediates the Warburg effect in clear cell renal carcinoma
    Gregg L Semenza
    Institute for Cell Engineering, Departments of Pediatrics, Medicine, Oncology, and Radiation Oncology, and McKusick Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Bioenerg Biomembr 39:231-4. 2007
    ..These findings delineate for the first time the molecular mechanisms underlying the Warburg effect in a human cancer...
  30. ncbi Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
    The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC).
  31. ncbi Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397)
    Rafael Manon
    University of Wisconsin, Madison, USA
    J Clin Oncol 23:8870-6. 2005
    ..PATIENTS AND METHODS: Patients with renal cell carcinoma, melanoma, or sarcoma; one to three brain metastases; and performance status of 0 to 2 were enrolled...
  32. ncbi Unusual solitary metastasis of the ciliary body in renal cell carcinoma
    Vito Mancini
    Urology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation DETO, University of Bari, Italy
    Int J Urol 15:363-5. 2008
    b>Renal cell carcinoma (RCC) usually metastasizes to the lung, liver, bone; ocular metastasis is uncommon...
  33. ncbi Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma
    Rainer Riesenberg
    Tumor Immunology Laboratory, LIFE Center, Department of Urology, University Clinic Grosshadern, Institute of Pathology, Ludwig Maximilians University Munich, Munich, Germany
    Clin Cancer Res 13:6993-7002. 2007
    ..Here, we analyzed the role of IDO in tumor growth and disease progression in patients with clear cell renal cell carcinoma (RCC).
  34. ncbi Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study
    Hans J Hammers
    Johns Hopkins University, Baltimore, Maryland, USA
    Mol Cancer Ther 9:1525-35. 2010
    ..of the vascular endothelial growth factor pathway have changed the medical management of metastatic renal cell carcinoma. Although treatment with TKIs has shown clinical benefit, these drugs will eventually fail patients...
  35. ncbi Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma
    Yasuyoshi Miyata
    Department of Urology, Nagasaki University School of Medicine, Japan
    Clin Cancer Res 12:4876-81. 2006
    ..The clinical significance and pathologic roles of phosphorylated HGFR/c-Met in renal cell carcinoma (RCC) are not fully understood; therefore, this study sought to clarify the possible role of two tyrosine ..
  36. ncbi Targeting mTOR in renal cell carcinoma
    Gary R Hudes
    Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Cancer 115:2313-20. 2009
    The mammalian target of rapamycin (mTOR) is clearly an important therapeutic target for advanced renal cell carcinoma (RCC), although its mechanisms of activation are not completely understood...
  37. ncbi Metastatic renal cell carcinoma to the thyroid gland
    Neal Murari Duggal
    Northeastern Ohio Universities College of Medicine and Pharmacy, Rootstown, OH, USA
    Endocr Pract 14:1040-6. 2008
    ..To examine the presentation, diagnosis, and appropriate management of renal clear cell carcinoma metastasis to the thyroid gland...
  38. ncbi Renal cell carcinoma, metastatic to the left ventricle
    Jaime Aburto
    Division of Cardiac Surgery, Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, TX 77030, USA
    Tex Heart Inst J 36:48-9. 2009
    Left ventricular metastases from renal cell carcinoma without vena caval or right atrial involvement are extremely rare...
  39. ncbi Cutaneous metastasis of renal cell carcinoma through percutaneous fine needle aspiration biopsy: case report
    Ghorbel Jilani
    Urology Department, Militairy Hospital of Tunis, 1008, Monfleury, Tunis, Tunisia
    Dermatol Online J 16:10. 2010
    A 39-year-old man, who had undergone left nephrectomy for renal cell carcinoma of clear cell type, was noted to have a solitary nodular shadow in the right lung on chest X-ray...
  40. ncbi Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review
    Sanjiv S Agarwala
    Oncology and Hematology, St Luke s Cancer Center, 801 Ostrum Street, Bethlehem, Pennsylvania 18015, USA
    Oncologist 15:236-45. 2010
    Historically, there have been few treatment options for patients with advanced renal cell carcinoma (RCC) besides immunotherapy with interleukin-2 and interferon (IFN)-alpha...
  41. ncbi Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients
    Thomas Schwaab
    Medical Oncology Immunotherapy Group, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Clin Cancer Res 15:4986-92. 2009
    To evaluate the clinical and immunologic outcomes of DC (dendritic cell) vaccine with interleukin (IL)-2 and IFN-alpha 2a in metastatic renal cell carcinoma patients.
  42. ncbi Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2
    Annika Berntsen
    Department of Oncology, Copenhagen University Hospital at Herlev, Denmark
    J Immunother 33:425-34. 2010
    ..dendritic cell (DC) vaccination in combination with low-dose interleukin (IL)-2 in patients with metastatic renal cell carcinoma on the frequency of CD4+CD25highFoxp3+ Treg cells in peripheral blood...
  43. ncbi Prognostic significance of periodic acid-Schiff-positive patterns in clear cell renal cell carcinoma
    Amalia A Vartanian
    N N Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia
    Can J Urol 16:4726-32. 2009
    ..VM channels are revealed as periodic acid-Schiff (PAS)-positive patterns, and in some tumors their presence predicts clinical outcomes...
  44. ncbi Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
    Timo Purmonen
    Centre for Pharmaceutical Policy and Economics, Department of Social Pharmacy, University of Kuopio, Kuopio, Finland
    Clin Ther 30:382-92. 2008
    Cytokine therapy is currently used as first-line treatment of metastatic renal cell carcinoma (mRCC). Until recently, treatments with proven efficacy after the failure of first-line cytokine therapy were not available...
  45. ncbi Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients
    Emilie Viey
    Institut National de la Santé et de la Recherche Médicale U753, from Institut Fédératif de Recherche 54 Villejuif, France
    J Immunother 31:313-23. 2008
    ..tumors and can be expanded as potent cytotoxic effectors from peripheral blood mononuclear cells of most renal cell carcinoma (RCC) patients, using a structural analog of nonconventional T-cell receptor gamma9delta2 ligand, ..
  46. ncbi Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma
    Tomohiro Domoto
    Laboratory of Host Defense, University of Shizuoka, Shizuoka, Japan
    Cancer Sci 98:77-82. 2007
    This study aimed to analyze expression of S100A10, annexin II and B-FABP genes in renal cell carcinoma (RCC) and their potential value as tumor markers...
  47. ncbi Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more
    Andre Berger
    USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90080, USA
    J Urol 182:2172-6. 2009
    ..We present oncological outcomes at a followup of 10 years or greater after laparoscopic radical nephrectomy for cancer...
  48. ncbi Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Cancer Treat Rev 36:16-23. 2010
    Five targeted agents have shown efficacy in advanced renal cell carcinoma. These agents were evaluated in pivotal phase III clinical trials using different treatment settings and different patient populations...
  49. ncbi Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis
    K Xu
    Department of Urology, Huashan Hospital, Fudan University, Shanghai, China
    Cancer Gene Ther 17:212-22. 2010
    ..is a main responder to intracellular hypoxia and is overexpressed in many human cancers, including renal cell carcinoma (RCC)...
  50. ncbi Robotic assisted laparoscopic partial nephrectomy for suspected renal cell carcinoma: retrospective review of surgical outcomes of 35 cases
    Sam B Bhayani
    Department of Surgery, Division of Urology, Washington University School of Medicine, Saint Louis, MO, USA
    BMC Surg 8:16. 2008
    ..Robotic assistance may augment partial nephrectomy by aiding in dissection and renal reconstruction. In this communication we describe the surgical outcomes of 35 patients undergoing robotic partial nephrectomy...
  51. ncbi Effects of a KiSS-1 peptide, a metastasis suppressor gene, on the invasive ability of renal cell carcinoma cells through a modulation of a matrix metalloproteinase 2 expression
    Kunihiko Yoshioka
    Department of Urology, Tokyo Medical University 6 7 1 Nishi shinjuku, Shinjuku ku, Tokyo, Japan
    Life Sci 83:332-8. 2008
    ..how KiSS-1 works and to assess effects of a synthesized truncated KiSS-1 protein on the invasive ability of renal cell carcinoma (RCC) cells...
  52. ncbi C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients
    Scott S Tykodi
    Program in Immunology, Fred Hutchinson Cancer Research Center
    Clin Cancer Res 14:5260-9. 2008
    Tumor regression has been observed in some patients with metastatic renal cell carcinoma (RCC) after nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)...
  53. ncbi Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
    Annika Berntsen
    Department of Oncology Section, Center for Cancer Immunotherapy, Herlev Hospital, Herlev, Denmark
    J Immunother 31:771-80. 2008
    ..T-cell response, and clinical response after treatment with a DC-based vaccine in patients with metastatic renal cell carcinoma. Twenty-seven patients with progressive cytokine-refractory metastatic renal cell carcinoma were vaccinated ..
  54. ncbi Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN
    Emma R Woodward
    Cancer Research UK Renal Molecular Oncology Group and Department of Medical and Molecular Genetics, University of Birmingham and West Midlands Regional Genetics Service, Birmingham Women s Hospital, United Kingdom
    Clin Cancer Res 14:5925-30. 2008
    Familial renal cell carcinoma (RCC) is genetically heterogeneous. The most common histopathologic subtype of sporadic and familial RCC is clear cell (cRCC) and von Hippel-Lindau (VHL) disease is the most common cause of inherited cRCC...
  55. ncbi Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review
    Kiran Gupta
    Abt Associates Inc, HERQuLES, 181 Spring Street, Lexington, MA 02421, United States
    Cancer Treat Rev 34:193-205. 2008
    b>Renal cell carcinoma (RCC), the most common form of kidney cancer, initially has an asymptomatic clinical course; 25-30% of patients present with metastatic disease at time of diagnosis...
  56. ncbi Low adiponectin levels are associated with renal cell carcinoma: a case-control study
    Themistoklis N Spyridopoulos
    Department of Hygiene and Epidemiology, Athens University Medical School, Goudi, Athens, Greece
    Int J Cancer 120:1573-8. 2007
    ..Because obesity is a risk factor for renal cell carcinoma (RCC), we hypothesized that low adiponectin levels are associated with RCC...
  57. ncbi Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma
    Yao Zhang
    Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Yi Xue Yuan Road, Chongqing, P R China
    Int J Oncol 36:133-40. 2010
    ..The results showed that exosomes derived from IL-12-anchored renal cancer cells expressed renal cell carcinoma-associated antigen G250 and GPI-IL-12...
  58. ncbi Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells
    Yong Zhong
    Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, China
    Cancer Lett 299:150-60. 2010
    ..In this study, we sought to enrich CSCs from the renal cell carcinoma (RCC) cell line SK-RC-42 using the sphere culture system and characterize their immunophenotype...
  59. ncbi Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma
    M A T Hildebrandt
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 29:5724-8. 2010
    The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically altered by the development of metastatic recurrence. However, there are very few indicators that can predict which patient will develop a recurrence...
  60. ncbi A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
    ..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
  61. ncbi Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma
    Natalie C Twine
    Discovery Medicine, Wyeth Research, Cambridge, Massachusetts 02140, USA
    Cancer Res 63:6069-75. 2003
    ..We identified transcripts expressed differentially between PBMCs from renal cell carcinoma patients and normal subjects, some of which appear to reflect specific immune responses of circulating ..
  62. ncbi Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials
    Grace X Zhou
    Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Urology 75:257-61. 2010
    ..Recent studies found protein levels of CAIX, quantified using immunohistochemistry, correlated with clinical outcomes and therapeutic response to immunotherapy in advanced stage clear cell renal cell carcinoma (CCRCC).
  63. ncbi Small renal tumors: correlation of clinical and pathological features with tumor size
    Sascha Pahernik
    Department of Urology, Johannes Gutenberg University, Mainz, Germany
    J Urol 178:414-7; discussion 416-7. 2007
    We analyzed the association between tumor diameter and pathological stage, histological subtype, tumor grade and the incidence of metastases in renal cell carcinoma with a diameter of up to 4 cm (clinical stage T1a).
  64. ncbi Prognostic impact of perirenal fat or adrenal gland involvement in patients with pT3b renal cell carcinoma
    Tetsuo Fujita
    Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    Urology 69:839-42. 2007
    To analyze the prognostic impact of the pT3a factors, perirenal fat or adrenal gland involvement, in patients with pT3b renal cell carcinoma (RCC).
  65. ncbi Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy
    Kazuhiro Araki
    Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
    Urology 68:1178-82. 2006
    To identify the prognostic factors in patients with recurrent renal cell carcinoma after nephrectomy, various factors were assessed, with special attention to serum immunosuppressive acidic protein (IAP) and its doubling time.
  66. ncbi [Renal cell carcinoma: prognostic factors and staging]
    Antonio Jalón Monzón
    Servicio de Urologia 1, Hospital Universitario Central de Asturias, Oviedo, Asturias, Espana
    Arch Esp Urol 60:125-36. 2007
    To evaluate the prognostic significance of the 2002 TNM tumor classification for renal cell carcinoma, as well as other factors intervening in its survival.
  67. ncbi Microvascular tumor invasion: prognostic significance in low-stage renal cell carcinoma
    Khaled Madbouly
    Department of Surgery, Division of Urology, King Fahad National Guard Hospital, Riyadh, Saudi Arabia
    Urology 69:670-4. 2007
    To evaluate the role of microvascular tumor invasion (MVI) in clinical behavior and prognosis of low-stage renal cell carcinoma.
  68. ncbi Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor
    Marcos F Dall'oglio
    Division of Urology, University of Sao Paulo Medical School, Sao Paulo, Brazil
    BJU Int 100:552-5. 2007
    To evaluate the role of microvascular invasion (MVI) in the primary lesion for predicting tumour behaviour in patients with renal cell carcinoma (RCC), as reliable clinical prognostic factors would be very valuable.
  69. ncbi Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma
    Leopoldo Alves Ribeiro Filho
    Division of Urology, Medical School, University of Sao Paulo, Sao Paulo, Brazil
    J Urol 178:425-8; discussion 428. 2007
    The biological behavior and clinical outcome of renal cell carcinoma are difficult to predict...
  70. ncbi Does stage T3a renal cell carcinoma embrace a homogeneous group of patients?
    Ofer N Gofrit
    Department of Urology and Pathology, Hadassah University Hospital, Jerusalem, Israel
    J Urol 177:1682-6. 2007
    b>Renal cell carcinoma invading the perinephric fat is classified as a stage T3a tumor in the 2002 TNM version. Based on long-term followup we examined the prognostic significance of this definition.
  71. ncbi A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy
    Brian R Lane
    Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Urol 178:429-34. 2007
    ..We present novel nomograms that predict the likelihood of benign, likely indolent or potentially aggressive pathological findings based only on readily identifiable preoperative factors...
  72. ncbi Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    BJU Int 99:821-4. 2007
    ..of capsular involvement (invasion with no penetration) and collecting-system invasion in patients with stage I (pT1N0M0) and stage II (pT2N0M0) renal cell carcinoma (RCC), by evaluating the outcome of patients treated with nephrectomy.
  73. ncbi Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma
    Sang Eun Lee
    Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
    BJU Int 98:1228-32. 2006
    ..prognostic significance of common preoperative laboratory variables evaluated before surgery for clear cell renal cell carcinoma (RCC)...
  74. ncbi Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma
    Yoshinobu Komai
    Department of Urology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan
    BJU Int 99:77-80. 2007
    To evaluate the value of the preoperative serum C-reactive protein (CRP) level in the prognosis of patients with localized renal cell carcinoma (RCC).
  75. ncbi Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma
    Sang Eun Lee
    Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
    J Urol 176:1332-7; discussion 1337-8. 2006
    PURPOSE: We investigated the prognostic significance of macroscopic tumor necrosis in renal cell carcinoma. MATERIALS AND METHODS: We retrospectively analyzed the records of 485 patients who underwent surgical treatment for organ confined ..
  76. ncbi Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma
    Cheol Kwak
    Department of Urology, Seoul National University Hospital, Seoul, Korea
    J Surg Oncol 95:317-23. 2007
    The objective of the current study was to determine the significance of sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma (RCC).
  77. ncbi Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence
    Scott E Eggener
    Genitourinary Oncology Service, Division of Solid Tumor Oncology and Department of Urology, Memorial Sloan-Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 24:3101-6. 2006
    PURPOSE: Prognostic factors for patients with metastatic renal cell carcinoma (RCC) are well established. However, the risk profile is unknown for patients with recurrent RCC after a nephrectomy for localized disease...
  78. ncbi Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes
    Sascha Pahernik
    Department of Urology, Johannes Gutenberg University, Langenbeckstrasse 1, 55101 Mainz, Germany
    BJU Int 100:26-9. 2007
    To analyse the functional and oncological outcomes of surgical treatment of bilateral synchronous sporadic renal cell carcinoma (RCC).
  79. ncbi Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma
    Nguyen Ba Phuoc
    Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan
    Urology 69:843-8. 2007
    To simultaneously analyze multiple biologic markers to identify strong prognostic markers for disease-specific survival of patients with clear cell renal cell carcinoma (ccRCC).
  80. ncbi Surgical care, morbidity, mortality and follow-up after nephrectomy for renal cancer with extension of tumor thrombus into the inferior vena cava: retrospective study since 1990s
    Jerome Rigaud
    Clinique Urologique, Hotel Dieu, CHU Nantes, France
    Eur Urol 50:302-10. 2006
    ..The aim of our survey was to evaluate surgical care, morbidity, mortality and follow-up of patients who had undergone surgical exeresis of a renal cancer with extension of tumor thrombus into the inferior vena cava...
  81. ncbi Renal cell carcinoma: a clinicopathological follow-up study after radical nephrectomy
    Dragomir P Zubac
    Section of Urology, Department of Surgery, The Gade Institute, Haukeland University Hospital, Bergen, Norway
    Scand J Urol Nephrol 41:191-7. 2007
    ..significance of performance status, tumour stage, histological subtype, nuclear grade and histological tumour necrosis (HTN) in a population of consecutive patients subjected to radical nephrectomy for renal cell carcinoma (RCC).
  82. ncbi Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma
    Y Soini
    Department of Pathology, University of Oulu, Oulu, Finland
    APMIS 114:329-37. 2006
    ..Prx 2 was more abundantly expressed in low grade tumors, suggesting that this protein could play a role in preventing the development of oxidative damage, which in turn can lead to the activation of pathways leading to aggressive tumors...
  83. ncbi Impact of clinicopathological parameters in patients treated for renal cell carcinoma
    Marcos F Dall'oglio
    Division of Urology, University of Sao Paulo Medical School, Sao Paulo, Brazil
    J Urol 177:1687-91. 2007
    We determined the impact of clinical and pathological factors in the outcome of patients with renal cell carcinoma treated surgically.
  84. ncbi Serum ferritin in renal cell carcinoma: effect of tumor size, volume grade, and stage
    Kamal Jeet Singh
    Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
    Indian J Cancer 42:197-200. 2005
    To study the levels of serum ferritin in patients of renal cell carcinoma (RCC).
  85. ncbi [Comparison of endoscopic versus open radical nephrectomy for stage T1 and T2 renal cancer]
    Koji Mita
    Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University
    Hinyokika Kiyo 51:81-4. 2005
    ..nephrectomy (ERN) with those of open radical nephrectomy (ORN) in patients with stage T1 and stage T2 renal cell carcinoma during the period from 1995 to 2003...
  86. ncbi Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
    Matthew H T Bui
    Department of Urology, University of California, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 9:802-11. 2003
    Metastatic renal cell carcinoma (RCC) has a poor prognosis and an unpredictable course. To date, there are no molecular markers which can reliably predict RCC outcome...
  87. ncbi Clinicopathological study of renal cell carcinoma
    Tatsuya Nakatani
    Department of Urology, Osaka City University Graduate School of Medicine, 1 4 3 Asahi machi, Abeno Ku, Osaka 545 8585, Japan
    Oncol Rep 10:679-85. 2003
    We investigated the clinicopathological features of 153 patients with renal cell carcinoma who underwent nephrectomy at our institute from April 1992 to August 2001 and evaluated the prognostic significance of various clinical and ..
  88. ncbi Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma
    Akira Miyajima
    Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan
    Urology 61:1072-7. 2003
    ..of transforming growth factor-beta (TGF-beta) receptor (TbetaR) expression for the pathologic features in renal cell carcinoma (RCC) and the prognosis of 62 patients (Stage I, 4; Stage II, 28; Stage III, 11; and Stage IV, 19) who ..
  89. ncbi The association between social support, intrusive thoughts, avoidance, and adjustment following an experimental cancer treatment
    Danielle Devine
    Department of Behavioral Science, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Psychooncology 12:453-62. 2003
    ....
  90. ncbi Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma
    Jean Jacques Patard
    Service d Urologie, CHU Pontchaillou, rue Henri Le Guilloux, 35033 Rennes, France
    Eur Urol 44:226-32. 2003
    ..To compare renal tumors with respect to initial clinical presentation and assess the prognostic value of a symptom based classification...
  91. ncbi Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcome
    Kent G Krejci
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 62:641-6. 2003
    OBJECTIVES: To determine the clinicopathologic features associated with outcome in patients with sporadic renal cell carcinoma (RCC) treated with nephron-sparing surgery...
  92. ncbi A preoperative clinical prognostic model for non-metastatic renal cell carcinoma
    L Cindolo
    Department of Urology, Medical School of University Federico II, Naples, Italy
    BJU Int 92:901-5. 2003
    To develop a model to predict the outcome before surgery for non-metastatic renal cell carcinoma (RCC).
  93. ncbi Clinical outcome of renal cell cancer patients subjected to the simultaneous removal of the primary tumour and an intracaval thrombosis
    Markus Kuczyk
    Eur Urol 50:310. 2006
  94. ncbi The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy
    Axel Haferkamp
    Department of Urology, University of Heidelberg, Germany
    BJU Int 101:1243-6. 2008
    To assess whether under- or overweight at the time of surgery has any effect on the survival of the patients with renal cell carcinoma (RCC), as obesity increases the risk of developing RCC.
  95. ncbi Prognostic significance of primary-tumor extension, stage and grade of nuclear differentiation in patients with renal cell carcinoma
    E Fiori
    Dept of General Surgery Pietro Valdoni, University of Rome La Sapienza, Italy
    J Exp Clin Cancer Res 21:229-32. 2002
    Surgery remains the preferred therapy for renal cell carcinoma. The various adjunctive or complementary therapies currently yield disappointing results...
  96. ncbi Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy
    Luca Cindolo
    Urology Unit, G Rummo Hospital, Benevento, Italy
    Cancer 113:65-71. 2008
    ..UCLA) Integrated Staging System (UISS) prognostic score in patients nephrectomized for nonmetastatic renal cell carcinoma (RCC) has never been specifically addressed...
  97. ncbi Outcomes following partial nephrectomy by tumor size
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 180:1912-7. 2008
    ..We established long-term survival in patients following partial nephrectomy according to tumor size...
  98. ncbi The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses
    Beverley A Shannon
    Tissugen Pty Ltd, Perth, Western Australia, Australia
    J Urol 180:1257-61; discussion 1261. 2008
    ..We determined the safety and accuracy of preoperative needle core biopsy for diagnosing benign lesions among small incidental asymptomatic renal masses...
  99. ncbi Activation of PI3K is associated with reduced survival in renal cell carcinoma
    Axel S Merseburger
    Department of Urology, Eberhard Karls University Tubingen, Tubingen, Germany
    Urol Int 80:372-7. 2008
    ..of Akt pathway parameters PI3K, phosphatase and tensin homolog (PTEN), phosphor-Akt (p-Akt) and their combination, for their possible prognostic value in renal cell carcinoma (RCC). PTEN dephosphorylates the liquid product of PI3K.
  100. ncbi Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome
    A Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 166:54-8. 2001
    ..the 1987 to the 1997 version and suggest a modified tumor size cutoff point between T stages 1 and 2 for renal cell carcinoma. MATERIALS AND METHODS: We evaluated a database containing the records of 661 patients who underwent ..
  101. ncbi A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma
    Kang Su Cho
    Department of Urology, Urological Science Institute, Yonsei University, Seodaemun gu, Seoul, Korea
    Yonsei Med J 49:451-8. 2008
    To develop a reliable prognostic model for patients with metastatic renal cell carcinoma (RCC) based on features readily available in common clinical settings.

Research Grants82

  1. Targeting Tumor Angiogenesis with SAHA and Bevacizumab in Kidney Cancer
    Roberto Pili; Fiscal Year: 2007
    Tumor angiogenesis is critical for the development and progression of epithelial tumors including renal cell carcinoma (RCC)...
  2. Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma
    EUGENE D contact KWON; Fiscal Year: 2010
    b>Renal cell carcinoma (RCC) encompasses 90% of kidney cancers and 3% of adult cancers. In the U.S. alone, more than 30,000 new cases of RCC are diagnosed and nearly 13,000 patients die from RCC annually...
  3. Clinical Impact of B7-H Immune Cell Coregulators in Renal Cell Carcinoma
    Eugene Kwon; Fiscal Year: 2009
    b>Renal cell carcinoma (RCC) encompasses 90% of kidney cancers and 3% of adult cancers. In the U.S. alone, more than 30,000 new cases of RCC are diagnosed and nearly 13,000 patients die from RCC annually...
  4. Regulation of nitrogen catabolic gene expression in S cerevisiae
    Terrance G Cooper; Fiscal Year: 2010
    ..coronary artery disease, as antineoplastic agents in the treatment of estrogen-induced breast cancer and renal cell carcinoma, and as immunosuppressants following organ transplant surgery. In S...
  5. Regulation of nitrogen catabolic gene expression in S cerevisiae
    TERRANCE COOPER; Fiscal Year: 2007
    ..coronary artery disease, as antineoplastic agents in the treatment of estrogen-induced breast cancer and renal cell carcinoma, and as immunosuppressants following organ transplant surgery. In S...
  6. PAX2 INTERACTING PROTEINS IN DEVELOPMENT AND DISEASE
    Gregory Dressler; Fiscal Year: 2009
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, inluuding renal cell carcinoma, polycystic kidney disease, Wilms' tumor, and prostate carcinoma...
  7. Systemic AA Amyloidosis Inhibitors
    ALAN SNOW; Fiscal Year: 2004
    ..ankylosing spondylitis, inflammatory bowel diseases, tuberculosis, leprosy, Hodgkin's disease, renal cell carcinoma, and Familial Mediterranean Fever...
  8. Mechanism of Gene Repression in the Kidney
    SANJEEVKUMAR PATEL; Fiscal Year: 2009
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, including renal cell carcinoma, polycystic kidney disease, Wilms' tumor, and prostate carcinoma...
  9. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    Joseph Bonventre; Fiscal Year: 2007
    ..by epithelial cell dedifferentiation: ischemia, toxic renal injury, polycystic kidney disease and renal cell carcinoma. It is upregulated more than any other known protein with renal injury...
  10. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    JOSEPH VINCENT BONVENTRE; Fiscal Year: 2010
    ..by epithelial cell dedifferentiation: ischemia, toxic renal injury, polycystic kidney disease and renal cell carcinoma. It is upregulated more than any other known protein with renal injury...
  11. REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCER
    Debabrata Mukhopadhyay; Fiscal Year: 2010
    Most of the cases, the clear-cell renal cell carcinoma (RCC) express strikingly elevated baseline levels of vascular permeability factor also known as vascular endothelial growth factor (VEGF) rationalized their vascular nature...
  12. REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCER
    Debabrata Mukhopadhyay; Fiscal Year: 2009
    Most of the cases, the clear-cell renal cell carcinoma (RCC) express strikingly elevated baseline levels of vascular permeability factor also known as vascular endothelial growth factor (VEGF) rationalized their vascular nature...
  13. Identification of Biomarkers for Early Detection of Renal Cell Carcinoma
    Othon Iliopoulos; Fiscal Year: 2010
    The incidence of renal cell carcinoma (RCC) in United States has been projected to reach 56,000 cases/year in 2007 and has been rising since 1970 for both men and women and for whites as well as blacks...
  14. PAX2 INTERACTING PROTEINS IN DEVELOPMENT AND DISEASE
    Gregory R Dressler; Fiscal Year: 2010
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, inluuding renal cell carcinoma, polycystic kidney disease, Wilms'tumor, and prostate carcinoma...
  15. Analysis of the Novel Kinase ROR2: A New Molecular Target in Renal Cell Carcinoma
    Tricia Wright; Fiscal Year: 2007
    b>Renal cell carcinoma (RCC), a notoriously hard to treat solid tumor and the most common form of kidney cancer, has minimal sensitivity to traditional chemotherapy...
  16. Mechanism of Gene Repression in the Kidney
    Sanjeevkumar R Patel; Fiscal Year: 2010
    ..Furthermore, the Pax2 protein is overexpresed in a variety of disease states, including renal cell carcinoma, polycystic kidney disease, Wilms'tumor, and prostate carcinoma...
  17. Genetic Susceptibility Modifiers in Renal Cell Carcinoma
    Xifeng Wu; Fiscal Year: 2007
    ..Tobacco exposure is an established risk factor for renal cell carcinoma (RCC)...
  18. A Schizosaccharomyces pombe Model of Birt-Hogg-Dube Syndrome
    ELIZABETH HENSKE; Fiscal Year: 2007
    ..an autosomal dominant disorder characterized by skin hamartomas, lung cysts, spontaneous pneumothorax, and renal cell carcinoma. A germline mutation in the BHD gene was also recently found in a large kindred with dominantly inherited ..
  19. Genotype and phenotype predictors in therapy response in renal cell carcinoma
    William Lee; Fiscal Year: 2009
    Therapy of renal cell carcinoma (RCC) has been transformed in recent years by the efficacy of targeted agents that inhibit kinases involved in critical cellular signaling pathways and VEGF, a primary driver of tumor angiogenesis...
  20. MOLECULAR-GENETIC ANALYSIS OF 3P14 GENOMIC STABILITY
    Harry Drabkin; Fiscal Year: 2006
    ..rearrangement of any protein that interacts with VHL and its function may be germane to the development of renal cell carcinoma (RCC)...
  21. Genotype and phenotype predictors in therapy response in renal cell carcinoma
    Katherine L Nathanson; Fiscal Year: 2010
    Therapy of renal cell carcinoma (RCC) has been transformed in recent years by the efficacy of targeted agents that inhibit kinases involved in critical cellular signaling pathways and VEGF, a primary driver of tumor angiogenesis...
  22. TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
    Thomas S Griffith; Fiscal Year: 2010
    This year in the U.S. ~40,000 new cases of renal cell carcinoma (RCC) will be diagnosed and >13,000 deaths are expected from RCC...
  23. TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
    THOMAS GRIFFITH; Fiscal Year: 2009
    This year in the U.S. ~40,000 new cases of renal cell carcinoma (RCC) will be diagnosed and >13,000 deaths are expected from RCC...
  24. KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIR
    JOSEPH VINCENT BONVENTRE; Fiscal Year: 2010
    ..in various states characterized by epithelial cell dedifferentiation: ischemia, toxic renal injury, and renal cell carcinoma. We have cloned, and generated monoclonal and polyclonal antibodies to, the human, mouse, pig, dog, ..
  25. Wnt antagonist genes in kidney tumor progression and metastasis
    Rajvir Dahiya; Fiscal Year: 2010
    ..whether inactivation of Wnt antagonist genes is involved in the progression and metastasis of human renal cell carcinoma. Based on the preliminary data, we have screened several Wnt antagonist genes and have identified six genes ..
  26. Analysis of Somatic Mutations in Cancer of the Kidney
    WAYNE VEDECKIS; Fiscal Year: 2005
    ..in p53 result from tobacco smoke carcinogens), and because we have access to DNA from 1,141 newly diagnosed renal cell carcinoma cases in the INCO Central Europe Health Study (CEHS), this NCI R03 project will evaluate whether there is a ..
  27. Genetic Retargeted Human T-cells for RCC Immunotherapy
    Wayne Marasco; Fiscal Year: 2006
    b>Renal cell carcinoma (RCC) is the most prevalent malignancy within the kidney and the incidence is rising. Due to improved radiological evaluation, over 50% of the renal cancers are found incidentally...
  28. MDA-7/IL-24 and free radicals in renal cancer therapy
    Paul Dent; Fiscal Year: 2007
    b>Renal Cell Carcinoma (RCC) is among the most lethal and difficult tumors to treat, particularly when disease has spread beyond the kidney and into the surrounding fascia; even intensive combinations of radio- and chemotherapy are not ..
  29. MDA-7/IL-24 and free radicals in renal cancer therapy
    Paul Dent; Fiscal Year: 2009
    b>Renal Cell Carcinoma (RCC) is among the most lethal and difficult tumors to treat, particularly when disease has spread beyond the kidney and into the surrounding fascia; even intensive combinations of radio- and chemotherapy are not ..
  30. Predictive Markers in Metastatic Renal Cancer
    Frederic M Waldman; Fiscal Year: 2010
    Metastatic renal cell carcinoma (RCC) is a dismal disease, with nearly uniform resistance to radiotherapy, chemotherapy and immunotherapy...
  31. Allogeneic T Cell Responses Against Renal Cell Carcinoma
    Edus Warren; Fiscal Year: 2007
    b>Renal cell carcinoma (RCC) is distinguished amongst solid tumors for its resistance to conventional chemo- and radiotherapy but its susceptibility, in a minority of patients, to immunologic manipulation...
  32. Predictive Markers in Metastatic Renal Cancer
    Frederic Waldman; Fiscal Year: 2009
    Metastatic renal cell carcinoma (RCC) is a dismal disease, with nearly uniform resistance to radiotherapy, chemotherapy and immunotherapy...
  33. Targeting Novel T Cell Antigens on Renal Cell Carcinoma
    SCOTT TYKODI; Fiscal Year: 2007
    Metastatic renal cell carcinoma (RCC) is poorly responsive to most conventional cancer therapy, but regression of metastatic RCC is seen in 10-20% of patients treated with non-specific immunotherapies such as interleukin-2 or interferon-(..